08.30 - 10.00
|
SESSION III - IMMUNE ONCOLOGY (CLINIC)
|
CHAIRS: Jean-Francois Rossi, Berksoy Sahin
|
08.30 - 08.55
|
Allogenic Transplantation as a Model for Immune Therapy in Oncology
|
Patrice Céballos
|
08.55 - 09.20
|
mAb Biosimilars
|
Bülent Gümüşel
|
09.20 - 09.45
|
CAR T Therapy for Solid Tumors
|
Prasad Adusumilli
|
09.45 - 10.00
|
Q & B
|
|
|
|
|
10.30 - 12.00
|
SESSION IV - HEAD AND NECK CANCER
|
CHAIRS: Musa Altun, Rasim Meral
|
10.30 - 10.55
|
HPV-Associated Head/Neck Cancer: New Stagings and New Treatments
|
Kübra Özkaya Toraman
|
10.55 - 11.20
|
Tumor-Related Factors Warranting Adjuvant Postoperative Therapy in Head and Neck Cancer
|
Musa Altun
|
11.20 - 11.45
|
p16-Negative Advanced Head and Neck Cancer
|
Bora Basaran
|
11.45 - 12.00
|
Q & A
|
|
|
|
|
12.00 - 13.00
|
LUNCH BREAK
|
|
|
|
|
13.00 - 14.30
|
SESSION V - NON-SMALL CELL LUNG CANCER
|
CHAIRS: Perran Fulden Yumuk
|
13.00 - 13.25
|
Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer
|
Mustafa Erman
|
13.25 - 13.50
|
Management of ALK Non-Small Cell Lung Cancer Through First and Subsequent Lines of Therapy
|
Fulden Yumuk
|
13.50 - 14.15
|
Immunotherapy in Small and Non-small Cell Lung Cancer; The Role of Immune Checkpoint Inhibitors in Frontline and Beyond Frontline Therapy
|
Başak Oyan Uluç |
14.15 - 14.30
|
Q & A
|
|
|
|
|
14.30 - 15.00
|
COFFEE BREAK
|
|
|
|
|
15.00 - 16.30
|
SESSION VI - EARLY BREAST CANCER
|
CHAIRS: Ozlem Er - Hasan Şenol Coşkun
|
15.00 - 15.25
|
Challenging Adjuvant Therapy in HER2+ Breast Cancer: Escalating or De-escalating ?
|
Çağatay Arslan
|
15.25 - 15.50
|
Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings
|
Ozlem Er
|
15.50 - 16.15
|
Adjuvant Therapy in ER+ HER2- Breast Cancer: Chemotherapy or Not?
|
Mehmet Ali Kaplan
|
16.15 - 16.30
|
Q & A
|
|
|
|
|
16.30 - 18.00
|
SESSION VII - COLORECTAL CANCER
|
CHAIRS: Mahmut Gümüş
|
16.30 - 16.55
|
Is Shortening the Duration of Adjuvant Treatment is Eligible in Early Staged Colon Cancer?
|
Ece Esin
|
16.55 - 17.20
|
Is Tumor Sideness, Biomarkers or Molecular Subtype Classification More Predictive for the Treatment of Unresectable Metastatic Colon Cancer?
|
Gökhan Demir
|
17.20 - 17.45
|
Systemic Therapy for Potentially Resectable Metastatic Rectal Cancer
|
Dilek erdem
|
17.45 - 18.00
|
Q & A
|
|
|
|
|